Peter Salzmann, CEO of Immunovant, Inc. ($IMVT), made two open market sales of company shares over the past year, totaling nearly $489,000. His latest sale occurred on April 16, 2025. These transactions rank 6,511th among 11,678 insiders in our database, well below the average sale value of $8.6 million across 6.4 transactions per insider. Salzmann recorded no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| April 16, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 8321 | $14.89 | 1,178,191.0000 | 0 | 0.70% | 0.00% |
| April 9, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 28094 | $12.99 | 1,186,512.0000 | 0 | 2.31% | 0.00% |
| April 1, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | A | Common Stock | 265820 | $0.00 | 1,214,606.0000 | 0 | 28.02% | 0.00% |
| April 1, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | A | Stock Option (right to buy) | 374395 | $0.00 | 374,395.0000 | 0 | 9999.99% | 0.00% |
| Feb. 19, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 15439 | $20.86 | 948,786.0000 | 0 | 1.60% | 0.00% |
| Jan. 15, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 415 | $24.19 | 964,225.0000 | 0 | 0.04% | 0.00% |
| Jan. 15, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 8352 | $23.81 | 964,640.0000 | 0 | 0.86% | 0.00% |
| Jan. 8, 2025 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 5105 | $24.10 | 972,992.0000 | 0 | 0.52% | 0.00% |
| Nov. 20, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 16692 | $25.45 | 978,097.0000 | 0 | 1.68% | 0.00% |
| Oct. 16, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 9095 | $28.79 | 994,789.0000 | 0 | 0.91% | 0.00% |
| Oct. 9, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 4460 | $29.56 | 1,003,884.0000 | 0 | 0.44% | 0.00% |
| Aug. 21, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 598 | $32.32 | 1,008,344.0000 | 0 | 0.06% | 0.00% |
| Aug. 21, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 14470 | $31.84 | 1,008,942.0000 | 0 | 1.41% | 0.00% |
| July 17, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 8175 | $29.64 | 1,023,922.0000 | 0 | 0.79% | 0.00% |
| July 17, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 510 | $30.55 | 1,023,412.0000 | 0 | 0.05% | 0.00% |
| July 9, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 4619 | $28.06 | 1,032,097.0000 | 0 | 0.45% | 0.00% |
| May 30, 2024 | Corbus Pharmaceuticals Holdings, Inc. | $CRBP | Salzmann Peter | Not found | A | Common Stock, par value $0.0001 per share | 2783 | $0.00 | 2,783.0000 | 0 | 9999.99% | 0.00% |
| May 22, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 16163 | $29.65 | 1,036,716.0000 | 0 | 1.54% | 0.00% |
| May 16, 2024 | Corbus Pharmaceuticals Holdings, Inc. | $CRBP | Salzmann Peter | Director | A | Stock Option (right to buy) | 2783 | $0.00 | 2,783.0000 | 0 | 9999.99% | 0.00% |
| April 17, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 26365 | $28.80 | 1,060,593.0000 | 0 | 2.43% | 0.00% |
| April 17, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 7714 | $29.94 | 1,052,879.0000 | 0 | 0.73% | 0.00% |
| April 9, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 4807 | $31.18 | 1,086,958.0000 | 0 | 0.44% | 0.00% |
| April 2, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | A | Common Stock | 160534 | $0.00 | 1,091,765.0000 | 0 | 17.24% | 0.00% |
| April 2, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | A | Stock Option (right to buy) | 200667 | $0.00 | 200,667.0000 | 0 | 9999.99% | 0.00% |
| Feb. 22, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 13454 | $36.15 | 931,231.0000 | 0 | 1.42% | 0.00% |
| Jan. 5, 2024 | Immunovant, Inc. | $IMVT | Salzmann Peter | Chief Executive Officer | S | Common Stock | 3824 | $38.59 | 944,685.0000 | 0 | 0.40% | 0.00% |
| May 18, 2023 | Corbus Pharmaceuticals Holdings, Inc. | $CRBP | Salzmann Peter | Director | A | Stock Option (right to buy) | 5300 | $0.00 | 5,300.0000 | 0 | 9999.99% | 0.00% |